Here, we perform a comprehensive multimodal assessment of PTPRZ1 in glioblastoma, demonstrate that it is a highly attractive immunotherapeutic target, and develop an off-the-shelf TCR-T therapy which is, in principle, applicable for all HLA-A*02+ glioma patients. The gene discussed is PTPRZ1; the disease is glioma.